iOrganBio Appoints AI and Life Sciences Veteran Jessica Owens to Board

In a move that signals its ambitions to scale AI-driven cell manufacturing, iOrganBio has appointed Jessica Owens to its Board of Directors. Owens, a seasoned venture investor and serial founder, brings over 20 years of experience building and scaling companies at the intersection of life sciences, health technology, and AI. She co-founded GRAIL, which raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson, and serves as co-founder and General Partner at Initiate Ventures. iOrganBio says her counsel will be invaluable as it scales CellForge, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies. The full announcement, including downloadable images and bios, can be viewed by clicking here.

iOrganBio is an innovator in intelligent cell manufacturing that is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). The company is based at BioLabs in Chapel Hill, NC. Its core platform, CellForge™, uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the heart of CellForge is iOrganBio’s functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.

With Owens joining the board, iOrganBio is poised to accelerate its mission of transforming human cell production. The company's AI-powered platform addresses a critical bottleneck in the field: the inability to consistently manufacture cells and organoids at scale for in vitro modeling and cell therapies. By applying engineering precision to biology, iOrganBio aims to make cell manufacturing predictable and scalable, which could significantly reduce the cost and time of developing new treatments. This appointment underscores the growing convergence of AI and life sciences, as investors and entrepreneurs recognize the potential of intelligent manufacturing to unlock new frontiers in medicine.